News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.
Novo Nordisk's fling with Hims & Hers ends in a bust-up
In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass compounding and deceptive marketing" of what it claimed were "illegitimate, knockoff versions" of its obesity therapy Wegovy (semaglutide).
9hon MSN
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...
StockStory.org on MSN18h
Hims & Hers Health (HIMS) Stock Trades Down, Here Is WhyShares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker ...
Zacks Investment Research on MSN4d
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...
Hims & Hers Health (NYSE:HIMS) recently announced the introduction of affordable access to Wegovy, a significant move aimed at improving obesity treatment options. This, along with strong Q1 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback